Publication | Open Access

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study

Cancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsAdvanced Cancer PatientsImmunologyImmune Checkpoint InhibitorDermatologyLonger Overall SurvivalImmunotherapyOncologyTumor MicroenvironmentSkin Cancer